Cargando…

Bevacizumab in recurrent WHO grades II–III glioma

PURPOSE: The management of recurrent WHO grades II–III (rGII–III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment. METHODS: In this retrospective study, the main inclusion criteria were as follows: adult patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Annakib, Soufyan, Rigau, Valérie, Darlix, Amélie, Gozé, Catherine, Duffau, Hugues, Bauchet, Luc, Jarlier, Marta, Fabbro, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391542/ https://www.ncbi.nlm.nih.gov/pubmed/37534252 http://dx.doi.org/10.3389/fonc.2023.1212714

Ejemplares similares

A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain
por: Parisot, Sarah, et al.
Publicado: (2016)

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas
por: Rème, Thierry, et al.
Publicado: (2013)

Identification of CRYAB(+) KCNN3(+) SOX9(+) Astrocyte-Like and EGFR(+) PDGFRA(+) OLIG1(+) Oligodendrocyte-Like Tumoral Cells in Diffuse IDH1-Mutant Gliomas and Implication of NOTCH1 Signalling in Their Genesis
por: Augustus, Meera, et al.
Publicado: (2021)

Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study
por: Fabbro-Peray, Pascale, et al.
Publicado: (2018)

Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth
por: Leventoux, N., et al.
Publicado: (2020)

Repeated Awake Surgical Resection(s) for Recurrent Diffuse Low-Grade Gliomas: Why, When, and How to Reoperate?
por: Duffau, Hugues
Publicado: (2022)

SLUG and Truncated TAL1 Reduce Glioblastoma Stem Cell Growth Downstream of Notch1 and Define Distinct Vascular Subpopulations in Glioblastoma Multiforme
por: Guelfi, Sophie, et al.
Publicado: (2021)

Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network
por: Darlix, Amélie, et al.
Publicado: (2019)

Can Non-invasive Brain Stimulation Be Considered to Facilitate Reoperation for Low-Grade Glioma Relapse by Eliciting Neuroplasticity?
por: Duffau, Hugues
Publicado: (2020)

RT-05 THE RESULTS OF GAMMA KNIFE RADIOSURGERY WITH BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GRADE II/III GLIOMAS
por: Asanome, Taku, et al.
Publicado: (2019)

Dynamic Interplay between Lower-Grade Glioma Instability and Brain Metaplasticity: Proposal of an Original Model to Guide the Therapeutic Strategy
por: Duffau, Hugues
Publicado: (2021)

Network Plasticity and Intraoperative Mapping for Personalized Multimodal Management of Diffuse Low-Grade Gliomas
por: Ghinda, Cristina Diana, et al.
Publicado: (2017)

What Does Quality of Care Mean in Lower-Grade Glioma Patients: A Precision Molecular-Based Management of the Tumor or an Individualized Medicine Centered on Patient’s Choices?
por: Taillandier, Luc, et al.
Publicado: (2021)

Reply to: Letter to the Editor Regarding Anesthesia Management for Low-Grade Glioma Awake Surgery: A European Low-Grade Glioma Network Survey
por: Madadaki, Catarina, et al.
Publicado: (2020)

Sexual Dysfunction of Patients with Diffuse Low-Grade Glioma: A Qualitative Review of a Neglected Concern
por: Lombard, Arnaud, et al.
Publicado: (2022)

Brain Plasticity Profiling as a Key Support to Therapeutic Decision-Making in Low-Grade Glioma Oncological Strategies
por: Ng, Sam, et al.
Publicado: (2023)

Awake Surgery for Left Posterior Insular Low-Grade Glioma Through the Parietorolandic Operculum: The Need to Preserve the Functional Connectivity. A Case Series
por: Duffau, Hugues
Publicado: (2022)

White Matter Tracts and Diffuse Lower-Grade Gliomas: The Pivotal Role of Myelin Plasticity in the Tumor Pathogenesis, Infiltration Patterns, Functional Consequences and Therapeutic Management
por: Duffau, Hugues
Publicado: (2022)

Asymmetric Distribution of GFAP in Glioma Multipotent Cells
por: Guichet, Pierre-Olivier, et al.
Publicado: (2016)

Functional Mapping before and after Low-Grade Glioma Surgery: A New Way to Decipher Various Spatiotemporal Patterns of Individual Neuroplastic Potential in Brain Tumor Patients
por: Duffau, Hugues
Publicado: (2020)

A Personalized Longitudinal Strategy in Low-Grade Glioma Patients: Predicting Oncological and Neural Interindividual Variability and Its Changes over Years to Think One Step Ahead
por: Duffau, Hugues
Publicado: (2022)

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
por: Bovi, Joseph A., et al.
Publicado: (2020)

The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome-Guided Therapeutic Attitude
por: Silva, Melissa, et al.
Publicado: (2022)

Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma
por: Wiestler, Benedikt, et al.
Publicado: (2016)

Vascular Transdifferentiation in the CNS: A Focus on Neural and Glioblastoma Stem-Like Cells
por: Guelfi, Sophie, et al.
Publicado: (2016)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

T2 mapping of molecular subtypes of WHO grade II/III gliomas
por: Kern, Maike, et al.
Publicado: (2020)

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis
por: Cho, Se Jin, et al.
Publicado: (2020)

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
por: Kulinich, Daniel P., et al.
Publicado: (2021)

Surgery for Malignant Brain Gliomas: Fluorescence-Guided Resection or Functional-Based Resection?
por: Duffau, Hugues
Publicado: (2019)

COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2019)

Homotopic redistribution of functional connectivity in insula-centered diffuse low-grade glioma
por: Almairac, Fabien, et al.
Publicado: (2021)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics
por: Relier, S., et al.
Publicado: (2022)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Transient immediate postoperative homotopic functional disconnectivity in low-grade glioma patients
por: Coget, Arthur, et al.
Publicado: (2018)

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
por: Zhang, Yu-An, et al.
Publicado: (2016)

Glioma stem cells invasive phenotype at optimal stiffness is driven by MGAT5 dependent mechanosensing
por: Marhuenda, Emilie, et al.
Publicado: (2021)

Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit
por: Obara, Tiphaine, et al.
Publicado: (2020)

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ufgar45kikvtuvqqvnlujvb2da